Poongjeon Pharmacy
Key metrics
Earnings
| Revenue, Q3 2026 | ₩10.4bn |
|---|---|
| Revenue QoQ | -13.1% |
| Revenue YoY | Not available |
| Operating income, Q3 2026 | -₩560m |
| Operating income QoQ | +43.2% |
| Operating income YoY | Not available |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩2.0bn |
|---|---|
| Rights offering new shares, last 12 months | 1,996,812 shares |
| Potential new shares, last 12 months | 4,463,078 shares (1 upward conversion price adjustment not netted) |
| Potential new shares, % of shares | 46.3% (1 upward conversion price adjustment not netted) |
| Conversion price adjustments, last 12 months | 4 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 10 |
|---|---|
| DART filings, previous 3 months | 12 |
Insider transactions
| Open-market buys, last 12 months (shares) | 267,335 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩710m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 267,335 shares |
| Insiders who bought, last 12 months | 1 |
Insider transactions (last 12 months)
Open-market buys: 267,335 shares (₩710m). Open-market sells: 0 shares (₩0). Net open-market buying: +267,335 shares. Insiders who bought: 1.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Aria Singisuljohap Je95ho (10%+ shareholder) | Other (Other decrease) | 0 shares | — | — | |
| Nov 11, 2026 | Yuta Singisuljohap Je82ho (10%+ shareholder) | Other (Other decrease) | 0 shares | — | — | |
| Jun 30, 2026 | Koni Singisuljohap Je63ho (10%+ shareholder) | Other (New report) | +429,530 shares | ₩3,725 | ₩1.6bn | |
| Jun 30, 2026 | Koni Singisuljohap Je63ho (10%+ shareholder) | Other (New report) | +432,900 shares | ₩4,620 | ₩2.0bn | |
| Jun 30, 2026 | Koni Singisuljohap Je63ho (10%+ shareholder) | Other (Third-party placement) | +796,812 shares | ₩2,510 | ₩2.0bn | |
| Jun 9, 2026 | Kim Yu-jeong (Registered director) | Open-market buy | +112,711 shares | ₩2,662 | ₩300m | |
| Jun 8, 2026 | Kim Yu-jeong (Registered director) | Open-market buy | +4,624 shares | ₩2,600 | ₩12m | |
| Jun 5, 2026 | Kim Yu-jeong (Registered director) | Open-market buy | +52,649 shares | ₩2,677 | ₩141m | |
| Jun 4, 2026 | Kim Yu-jeong (Registered director) | Open-market buy | +19,000 shares | ₩2,655 | ₩50m | |
| Jun 2, 2026 | Kim Yu-jeong (Registered director) | Open-market buy | +78,351 shares | ₩2,633 | ₩206m | |
| Apr 24, 2026 | Mareusia Singisuljohap Je77ho (10%+ shareholder) | Other (Reverse split) | -9,039,658 shares | — | — | |
| Apr 24, 2026 | Yuta Singisuljohap Je82ho (10%+ shareholder) | Other (Reverse split) | -3,651,007 shares | — | — | |
| Apr 24, 2026 | Aria Singisuljohap Je95ho (10%+ shareholder) | Other (Reverse split) | -3,787,879 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩23.8bn | -₩4.5bn |
| 2024 | ₩825m | -₩11.3bn |
| 2023 | ₩696m | -₩13.0bn |
Filing timeline
-
Poongjeon Pharmacy rights offering: 1,200,000 new shares, ₩3.0bn
Poongjeon Pharmacy filed a rights offering for 1,200,000 new shares, equal to 12.5% of existing shares by our calculation, with an issue amount of ₩3.0bn. The allocation method is third-party allotment and the main purpose of the funds is operating funds. The issue amount equals 12.6% of FY2025 revenue by our calculation.